Which has better earnings & valuation, ALKS or GERN?

Alkermes has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alkermes $1.48B 4.75 $241.66M $0.38 109.87 Geron $183.88M 4.19 -$83.50M -$0.11 N/A

Is ALKS or GERN more profitable?

Alkermes has a net margin of 3.96% compared to Geron's net margin of -34.17%. Alkermes' return on equity of 4.15% beat Geron's return on equity. Company Net Margins Return on Equity Return on Assets Alkermes 3.96% 4.15% 2.19% Geron -34.17% -24.48% -10.30%

Does the media favor ALKS or GERN?

In the previous week, Alkermes had 5 more articles in the media than Geron. MarketBeat recorded 6 mentions for Alkermes and 1 mentions for Geron. Alkermes' average media sentiment score of 0.82 beat Geron's score of 0.51 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, PGEN or GERN?

Geron has higher revenue and earnings than Precigen. Geron is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Precigen $9.68M 314.52 -$250.64M -$1.04 N/A Geron $183.88M 4.19 -$83.50M -$0.11 N/A

Is PGEN or GERN more profitable?

Geron has a net margin of -34.17% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Geron's return on equity. Company Net Margins Return on Equity Return on Assets Precigen -183.98% 423.75% 84.39% Geron -34.17% -24.48% -10.30%

Does the media prefer PGEN or GERN?

In the previous week, Precigen had 10 more articles in the media than Geron. MarketBeat recorded 11 mentions for Precigen and 1 mentions for Geron. Geron's average media sentiment score of 1.54 beat Precigen's score of 0.60 indicating that Geron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 3 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Geron 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is DYN or GERN more profitable?

Dyne Therapeutics has a net margin of 0.00% compared to Geron's net margin of -34.17%. Geron's return on equity of -24.48% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dyne Therapeutics N/A -64.30% -50.33% Geron -34.17% -24.48% -10.30%

Does the media favor DYN or GERN?

In the previous week, Dyne Therapeutics had 14 more articles in the media than Geron. MarketBeat recorded 15 mentions for Dyne Therapeutics and 1 mentions for Geron. Geron's average media sentiment score of 1.54 beat Dyne Therapeutics' score of 0.01 indicating that Geron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Geron 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher valuation and earnings, ZLAB or GERN?

Geron has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zai Lab $460.16M 6.02 -$175.54M -$1.71 N/A Geron $183.88M 4.19 -$83.50M -$0.11 N/A

Is ZLAB or GERN more profitable?

Geron has a net margin of -34.17% compared to Zai Lab's net margin of -41.86%. Geron's return on equity of -24.48% beat Zai Lab's return on equity. Company Net Margins Return on Equity Return on Assets Zai Lab -41.86% -27.43% -16.72% Geron -34.17% -24.48% -10.30%

Does the media prefer ZLAB or GERN?

In the previous week, Zai Lab had 4 more articles in the media than Geron. MarketBeat recorded 5 mentions for Zai Lab and 1 mentions for Geron. Geron's average media sentiment score of 0.51 beat Zai Lab's score of -0.33 indicating that Geron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Geron 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, NAMS or GERN?

Geron has higher revenue and earnings than NewAmsterdam Pharma. Geron is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NewAmsterdam Pharma $22.50M 123.26 -$203.82M -$2.16 N/A Geron $183.88M 4.19 -$83.50M -$0.11 N/A

Does the media favor NAMS or GERN?

In the previous week, NewAmsterdam Pharma had 11 more articles in the media than Geron. MarketBeat recorded 12 mentions for NewAmsterdam Pharma and 1 mentions for Geron. Geron's average media sentiment score of 1.54 beat NewAmsterdam Pharma's score of 0.25 indicating that Geron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 2 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Geron 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Geron (GERN) Competitors

$1.20 -0.01 (-0.83%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.21 +0.01 (+0.83%)

As of 10/2/2026 07:50 PM Eastern

Compare

GERN vs. ALKS, PGEN, DYN, ZLAB, and NAMS

Should you buy Geron stock or one of its competitors? Geron's main competitors and comparable companies include Alkermes (ALKS), Precigen (PGEN), Dyne Therapeutics (DYN), Zai Lab (ZLAB), and NewAmsterdam Pharma (NAMS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Geron compare to Alkermes?

Alkermes (NASDAQ:ALKS) and Geron (NASDAQ:GERN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

Alkermes currently has a consensus price target of $54.47, indicating a potential upside of 30.47%. Geron has a consensus price target of $4.00, indicating a potential upside of 233.33%. Given Geron's higher probable upside, analysts plainly believe Geron is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Alkermes had 5 more articles in the media than Geron. MarketBeat recorded 6 mentions for Alkermes and 1 mentions for Geron. Alkermes' average media sentiment score of 0.82 beat Geron's score of 0.51 indicating that Alkermes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Geron	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alkermes has a net margin of 3.96% compared to Geron's net margin of -34.17%. Alkermes' return on equity of 4.15% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	3.96%	4.15%	2.19%
Geron	-34.17%	-24.48%	-10.30%

95.2% of Alkermes shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 4.6% of Alkermes shares are held by company insiders. Comparatively, 1.7% of Geron shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Alkermes has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market. Comparatively, Geron has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Alkermes has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	4.75	$241.66M	$0.38	109.87
Geron	$183.88M	4.19	-$83.50M	-$0.11	N/A

Summary

Alkermes beats Geron on 15 of the 17 factors compared between the two stocks.

How does Geron compare to Precigen?

Precigen (NASDAQ:PGEN) and Geron (NASDAQ:GERN) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

In the previous week, Precigen had 10 more articles in the media than Geron. MarketBeat recorded 11 mentions for Precigen and 1 mentions for Geron. Geron's average media sentiment score of 1.54 beat Precigen's score of 0.60 indicating that Geron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	3 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Geron	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

33.5% of Precigen shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 41.4% of Precigen shares are held by company insiders. Comparatively, 1.7% of Geron shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Precigen has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, Geron has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

Geron has a net margin of -34.17% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-183.98%	423.75%	84.39%
Geron	-34.17%	-24.48%	-10.30%

Geron has higher revenue and earnings than Precigen. Geron is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	314.52	-$250.64M	-$1.04	N/A
Geron	$183.88M	4.19	-$83.50M	-$0.11	N/A

Precigen currently has a consensus target price of $13.67, indicating a potential upside of 60.03%. Geron has a consensus target price of $4.00, indicating a potential upside of 233.33%. Given Geron's higher possible upside, analysts plainly believe Geron is more favorable than Precigen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Precigen beats Geron on 10 of the 17 factors compared between the two stocks.

How does Geron compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Geron (NASDAQ:GERN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Geron has higher revenue and earnings than Dyne Therapeutics. Geron is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A
Geron	$183.88M	4.19	-$83.50M	-$0.11	N/A

Dyne Therapeutics has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, Geron has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 9.5% of Dyne Therapeutics shares are held by company insiders. Comparatively, 1.7% of Geron shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Dyne Therapeutics currently has a consensus target price of $33.07, suggesting a potential upside of 117.58%. Geron has a consensus target price of $4.00, suggesting a potential upside of 233.33%. Given Geron's higher possible upside, analysts clearly believe Geron is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Dyne Therapeutics had 14 more articles in the media than Geron. MarketBeat recorded 15 mentions for Dyne Therapeutics and 1 mentions for Geron. Geron's average media sentiment score of 1.54 beat Dyne Therapeutics' score of 0.01 indicating that Geron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Geron	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Dyne Therapeutics has a net margin of 0.00% compared to Geron's net margin of -34.17%. Geron's return on equity of -24.48% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-64.30%	-50.33%
Geron	-34.17%	-24.48%	-10.30%

Summary

Dyne Therapeutics beats Geron on 9 of the 16 factors compared between the two stocks.

How does Geron compare to Zai Lab?

Zai Lab (NASDAQ:ZLAB) and Geron (NASDAQ:GERN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

Geron has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	6.02	-$175.54M	-$1.71	N/A
Geron	$183.88M	4.19	-$83.50M	-$0.11	N/A

Zai Lab presently has a consensus price target of $37.25, suggesting a potential upside of 53.10%. Geron has a consensus price target of $4.00, suggesting a potential upside of 233.33%. Given Geron's higher probable upside, analysts plainly believe Geron is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Zai Lab has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, Geron has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

In the previous week, Zai Lab had 4 more articles in the media than Geron. MarketBeat recorded 5 mentions for Zai Lab and 1 mentions for Geron. Geron's average media sentiment score of 0.51 beat Zai Lab's score of -0.33 indicating that Geron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Geron	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Geron has a net margin of -34.17% compared to Zai Lab's net margin of -41.86%. Geron's return on equity of -24.48% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-41.86%	-27.43%	-16.72%
Geron	-34.17%	-24.48%	-10.30%

41.7% of Zai Lab shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 4.9% of Zai Lab shares are held by insiders. Comparatively, 1.7% of Geron shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Geron beats Zai Lab on 9 of the 17 factors compared between the two stocks.

How does Geron compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and Geron (NASDAQ:GERN) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

Geron has a net margin of -34.17% compared to NewAmsterdam Pharma's net margin of -3,644.21%. Geron's return on equity of -24.48% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%
Geron	-34.17%	-24.48%	-10.30%

NewAmsterdam Pharma currently has a consensus price target of $49.73, suggesting a potential upside of 114.34%. Geron has a consensus price target of $4.00, suggesting a potential upside of 233.33%. Given Geron's higher possible upside, analysts clearly believe Geron is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Geron has higher revenue and earnings than NewAmsterdam Pharma. Geron is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	123.26	-$203.82M	-$2.16	N/A
Geron	$183.88M	4.19	-$83.50M	-$0.11	N/A

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 12.7% of NewAmsterdam Pharma shares are owned by insiders. Comparatively, 1.7% of Geron shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

NewAmsterdam Pharma has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market. Comparatively, Geron has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

In the previous week, NewAmsterdam Pharma had 11 more articles in the media than Geron. MarketBeat recorded 12 mentions for NewAmsterdam Pharma and 1 mentions for Geron. Geron's average media sentiment score of 1.54 beat NewAmsterdam Pharma's score of 0.25 indicating that Geron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	2 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Geron	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Geron beats NewAmsterdam Pharma on 9 of the 17 factors compared between the two stocks.

Get Geron News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GERN vs. The Competition

Export

Metric	Geron	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$777.39M	$3.87B	$7.14B	$13.17B
Dividend Yield	N/A	3.64%	2.53%	16.78%
P/E Ratio	-10.91	13.06	275.68	26.04
Price / Sales	4.19	1,394.71	662.25	102.14
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	3.43	16.63	10.93	6.31
Net Income	-$83.50M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-4.76%	-2.99%	-2.00%	-1.66%
1 Month Performance	-20.53%	-10.60%	-6.15%	-4.50%
1 Year Performance	-11.11%	19.44%	7.44%	2.06%

Geron Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GERN Geron	2.2102 of 5 stars	$1.20 -0.8%	$4.00 +233.3%	-13.0%	$777.39M	$183.88M	N/A	258
ALKS Alkermes	2.8174 of 5 stars	$40.54 +0.0%	$54.47 +34.4%	+33.6%	$6.80B	$1.48B	106.69	2,050
PGEN Precigen	3.8822 of 5 stars	$8.21 -4.1%	$13.67 +66.5%	+156.5%	$3.05B	$9.68M	N/A	47	Gap Up
DYN Dyne Therapeutics	3.3327 of 5 stars	$15.82 -1.8%	$33.07 +109.0%	+21.1%	$3.01B	N/A	N/A	258	Analyst Forecast Analyst Revision
ZLAB Zai Lab	1.8426 of 5 stars	$25.50 -3.2%	$37.25 +46.1%	-28.1%	$3.00B	$460.16M	N/A	1,784

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GERN) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Geron (GERN) Competitors